Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corona RemediesBOM:544644 +0.73%18 EBIT per Share is ₹32.06 as of Jun. 2026. GuruFocus rates BOM:544644 with a GF Score™ of 18/100. The stock has 4 warning signs investors should review. Among 812 Drug Manufacturers companies, Corona Remedies ranks better than 80.79% on this metric.
Corona Remedies's EBIT per Share for the
three
months ended in Jun. 2026 was ₹13.58.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was ₹32.06.
During the past 12 months, the average EBIT per Share Growth Rate of Corona Remedies was 156.20% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 33.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Corona Remedies's EBIT per Share or its related term are showing as below:
BOM:544644'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 33.3 Med: 33.3 Max: 33.3
Current: 33.3
During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Corona Remedies was 33.30% per year. The lowest was 33.30% per year. And the median was 33.30% per year.
BOM:544644's 3-Year EBIT Growth Rate is ranked better than 80.79% of 812
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs BOM:544644: 33.30
Corona Remedies's EBIT for the
three
months ended in Jun. 2026 was ₹831 Mil.
Corona Remedies (BOM:544644) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Corona Remedies EBIT per Share Related Terms
Corona Remedies EBIT per Share Historical Data
* Premium members only.
The historical data trend for Corona Remedies's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹32.06
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corona Remedies (BOM:544644) has a EBIT per Share of ₹32.06 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Corona Remedies and its competitors. According to the industry distribution chart, Corona Remedies ranks #156 out of 812 companies in the Drug Manufacturers industry, placing it in the top 19.2%.
Is Corona Remedies' EBIT per Share too high?
Corona Remedies' current EBIT per Share is ₹32.06. Based on the distribution chart, Corona Remedies ranks #156 out of 812 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Corona Remedies has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Corona Remedies' EBIT per Share compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Corona Remedies ranks #156 out of 812 companies for EBIT per Share. This places Corona Remedies in the top 19% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Corona Remedies and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corona Remedies's current EBIT per Share is ₹32.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corona Remedies stock overvalued right now?
Corona Remedies (BOM:544644) has a current EBIT per Share of ₹32.06. The current EBIT per Share is ₹32.06. Corona Remedies' overall GF Score™ is 18/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Corona Remedies (BOM:544644), the current EBIT per Share is ₹32.06 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Corona Remedies Ltd is mainly engaged in the business of manufacturing, trading and marketing of Pharmaceutical products. It is engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabetes, pain management, urology and other segments, such as Vitamin Minerals and Nutrients(VMN), gastrointestinal and respiratory therapies. The company's brands are B-29, myoril, Tricium, Cortel, and Obimet. The Company has only one reportable business segment i.e. Pharmaceuticals. The company has presence in India as well as Outside India. The company generates majority of revenue from India.
18GF Score
Get the complete analysis for BOM:544644
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544644 has been successfully added to your 
